Clot Imaging Using Photostable Nanodiamond.
Samuel J FrancisMarco D TorelliNicholas A NunnGowthami M ArepallyOlga A ShenderovaPublished in: Nanomaterials (Basel, Switzerland) (2023)
While thrombosis is the leading cause of morbidity and mortality in the United States, an understanding of its triggers, progression, and response to anticoagulant therapy is lacking. Intravital fluorescence microscopy has advanced the study of thrombus formation by providing targeted, multi-color contrast. However, photodegradation of fluorophores limits the application in longitudinal studies (e.g., clot progression and/or dissolution). Fluorescent nanodiamond (FND) is a fluorophore which utilizes intrinsic fluorescence of chromogenic centers within and protected by the diamond crystalline lattice. Recent developments in diamond processing have allowed for the controlled production of nanodiamonds emitting in green or red. Here, the use of FND to label blood clots and/or clot lysis is demonstrated and compared to commonly used organic fluorophores. Model ex vivo clots were formed with incorporated labeled fibrinogen to allow imaging. FND was shown to match the morphology of organic fluorophore labels absent of photobleaching over time. The addition of tissue plasminogen activator (tPa) allowed visualization of the clot lysis stage, which is vital to studies of both DVT and pulmonary embolism resolution.
Keyphrases
- pulmonary embolism
- single molecule
- high resolution
- fluorescent probe
- inferior vena cava
- living cells
- energy transfer
- quantum dots
- case control
- venous thromboembolism
- magnetic resonance
- cross sectional
- label free
- atrial fibrillation
- magnetic resonance imaging
- computed tomography
- pet imaging
- stem cells
- fluorescence imaging
- cancer therapy
- water soluble
- high speed
- optical coherence tomography
- drug delivery
- mesenchymal stem cells
- pet ct
- replacement therapy